Bio Synectics
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Bio Synectics - overview
Established
2004
Location
Seoul, -, South Korea
Primary Industry
Pharmaceuticals
About
Founded in 2004 and based in Seoul, South Korea, Bio-Synectics, Inc. develops pharmaceutical treatments using nanoparticles.
Current Investors
Korea Investment Partners
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.bio-synectics.com
Verticals
Nanotechnology
Company Stage
Mature
Total Amount Raised
Subscriber access only
Bio Synectics - timeline of key events
Bio Synectics - financials
| Fiscal Year Ended | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 |
|---|---|---|---|---|---|---|---|
| Revenue (USD) | 103,460,000 | 140,592,000 | 428,195,000 | 378,596,000 | - | - | - |
| % Revenue Growth (YoY) | - | 35.9% | 204.6% | (11.6%) | - | - | - |
| EBITDA (USD) | (524,826,997) | (779,831,000) | (980,480,000) | (946,010,000) | - | - | - |
| Operating Income (USD) | (647,924,787) | (891,763,000) | (1,089,362,000) | (1,144,816,000) | - | - | - |
| Operating Margin | (626.3%) | (634.3%) | (254.4%) | (302.4%) | - | - | - |
| % EBITDA Margin | (507.3%) | (554.7%) | (229.0%) | (249.9%) | - | - | - |
| NET Income (USD) | (899,514,521) | (1,153,678,000) | (1,045,592,000) | (1,115,092,000) | - | - | - |
| % Net Margin | (869.4%) | (820.6%) | (244.2%) | (294.5%) | - | - | - |
Bio Synectics - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.